

1. Record Nr.	UNINA9910583347503321
Autore	Rezaei Nima
Titolo	Vaccines for cancer immunotherapy : an evidence-based review on current status and future perspectives / / Nima Rezaei, Mahsa Keshavarz-Fathi
Pubbl/distr/stampa	London, United Kingdom : , : Academic Press, an imprint of Elsevier, , [2019] ©2019
ISBN	0-12-814040-2
Descrizione fisica	1 online resource (185 pages)
Disciplina	616.994061
Soggetti	Cancer - Immunotherapy
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Front Cover -- Vaccines for Cancer Immunotherapy -- Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives -- Copyright -- Contents -- List of Contributors -- Preface -- 1 - CANCER IMMUNOLOGY -- INNATE AND ADOPTIVE IMMUNITY -- ACTIVATING IMMUNE CELLS -- MATURE DCS -- CLASSICALLY ACTIVATED MACROPHAGES (M1) -- GRANULOCYTES -- B LYMPHOCYTES -- T HELPER LYMPHOCYTES -- CYTOTOXIC T LYMPHOCYTES -- T LYMPHOCYTES -- NATURAL KILLER T CELLS -- NATURAL KILLER CELLS -- INHIBITORY IMMUNE CELLS -- TOLEROGENTIC DCS -- ALTERNATIVELY ACTIVATED MACROPHAGES (M2S) -- MYELOID-DERIVED SUPPRESSOR CELLS -- REGULATORY T CELLS -- REGULATORY B CELLS -- IMMUNOEDITING HYPOTHESIS -- ELIMINATION -- Cells -- Interferons -- Perforin -- Tumor Cell Recognition -- EQUILIBRIUM -- ESCAPE -- Defects in Tumor Antigen Processing, Presentation, and Recognition -- Lack of Activating Mechanisms -- Inhibitory Mechanisms and Immunosuppressive State -- Resistant Tumor Cells -- REFERENCES -- 2 - IMMUNOTHERAPEUTIC APPROACHES IN CANCER -- HISTORY -- APPROACHES OF CANCER IMMUNOTHERAPY -- PASSIVE VERSUS ACTIVE IMMUNOTHERAPY -- PASSIVE IMMUNOTHERAPY FOR CANCER -- Cytokines -- Monoclonal Antibodies (mAbs) -- Adoptive Cell Therapy -- ACTIVE IMMUNOTHERAPY FOR CANCER -- Vaccines --

Peptide Vaccine -- Tumor Cell Vaccine -- Dendritic Cell Vaccine --
Genetic Vaccine -- Checkpoint Inhibitors -- Oncolytic Viruses --
MECHANISM-BASED IMMUNOTHERAPIES: INTERACTIONS BETWEEN
TUMOR CELLS AND THE IMMUNE SYSTEM -- TUMOR ANTIGEN
EXPRESSION, RELEASE AND PRESENTATION -- T CELL PRIMING AND
ACTIVATION -- TRAFFICKING AND INFILTRATION OF T CELLS TO
TUMOR -- TUMOR CELL RECOGNITION AND EFFECTOR FUNCTION OF T
CELLS -- REFERENCES -- 3 - VACCINES, ADJUVANTS, AND DELIVERY
SYSTEMS -- DEFINITION AND CLASSIFICATION -- CANCER VACCINE --
PREVENTIVE CANCER VACCINE.
THERAPEUTIC CANCER VACCINE -- ADJUVANTS -- NONSPECIFIC
ADJUVANTS -- CYTOKINES AND CHEMOKINES -- STIMULATORS OF THE
INNATE IMMUNE SYSTEM -- C-type Lectin Receptor Ligands -- RIG-like
Receptor Ligands -- Stimulator of Interferon Gene Ligands -- Toll like
Receptor Ligands -- TLR2 Agonists -- TLR3 Agonists -- TLR4 Agonists
-- TLR7 and TLR8 Agonists -- TLR9 Agonists -- Other
Immunomodulatory Adjuvants -- Adjuvant Systems -- VECTORS AND
DELIVERY SYSTEM -- ROUTE OF ADMINISTRATION -- REFERENCES -- 4
- TUMOR ANTIGENS -- INTRODUCTION -- IDENTIFICATION OF TUMOR
ANTIGENS -- OVEREXPRESSED PROTEINS AND MUTATED ANTIGENS IN
TUMOR CELLS -- EPITOPE SPREADING -- TUMOR-ASSOCIATED
ANTIGENS -- TUMOR-SPECIFIC ANTIGENS -- NEOANTIGENS --
GLYCOLIPIDS AND GLYCOPROTEINS AS ANTIGENS -- MONO-EPITOPE
VERSUS POLY-EPITOPE ANTIGEN -- REFERENCES -- 5 - STRATEGY OF
ALLOGENEIC AND AUTOLOGOUS CANCER VACCINES -- AUTOLOGOUS
CANCER VACCINES -- IN VIVO STUDIES AND CLINICAL IMPLICATIONS --
ALLOGENEIC CANCER VACCINES -- IN VITRO/IN VIVO STUDIES AND
CLINICAL IMPLICATIONS -- REFERENCES -- 6 - PERSONALIZED CANCER
VACCINE -- INTRODUCTION ON PERSONALIZED MEDICINE --
PERSONALIZED MEDICINE IN CANCER PATIENTS -- SCREENING OF
CANCER -- CLASSIFICATION OF TUMORS -- TARGETED THERAPY AND
USING PREDICTIVE BIOMARKERS -- SAFETY OF MEDICATION --
PROGNOSTIC BIOMARKERS -- NEOANTIGENS AND PERSONALIZED
CANCER VACCINES -- PERSONALIZED CANCER VACCINES IN CLINICAL
STUDIES -- WHOLE TUMOR CELL VACCINES -- PEPTIDE/PROTEIN-BASED
VACCINE -- IMMUNE CELL-BASED VACCINES -- GENETIC-BASED
VACCINE -- REFERENCES -- 7 - WHOLE TUMOR CELL VACCINE FOR
CANCER -- TUMOR CELL LYSATES -- TUMOR-DERIVED EXOSOMES --
IRRADIATED GENE-MODIFIED TUMOR CELL VACCINE -- CLINICAL
TRIALS -- APPROVED VACCINE -- ADVANTAGES AND DISADVANTAGES
-- OPTIMIZATION -- REFERENCES -- 8 - PEPTIDE AND PROTEIN
VACCINES FOR CANCER -- PEPTIDE-BASED VACCINE.
PROTEIN-BASED VACCINE -- MECHANISM OF ACTION -- CLINICAL
TRIALS -- PEPTIDE-BASED VACCINE -- Gp100 -- BLP25 -- PROTEIN
BASED VACCINE -- MAGE-A3 -- EGF-P64k -- ADVANTAGES AND
DISADVANTAGES -- OPTIMIZATION -- REFERENCES -- 9 - IMMUNE
CELL VACCINE FOR CANCER -- IMMUNE CELL VACCINE -- MECHANISM
OF ACTION -- CLINICAL TRIALS -- IMMATURE DENDRITIC CELLS
PULSED WITH TUMOR CELL LYSATES -- MATURE DENDRITIC CELLS
PULSED WITH TUMOR CELL LYSATES -- DENDRITIC CELLS LOADED WITH
TUMOR-DERIVED RNA -- DENDRITIC CELLS PULSED WITH PEPTIDES --
DENDRITIC CELLS LOADED WITH TUMOR CELLS -- APPROVED VACCINE
-- ADVANTAGES AND DISADVANTAGES -- OPTIMIZATION --
REFERENCES -- 10 - GENETIC VACCINE FOR CANCER -- MECHANISM OF
ACTION -- MECHANISM OF ACTION OF DNA VACCINES -- MECHANISM
OF ACTION OF RNA VACCINES -- DNA VACCINE -- CLINICAL TRIALS --
DELIVERY, IMMUNOGENICITY AND IMMUNE RESPONSE -- ADVERSE
EFFECTS -- RNA VACCINE -- CLINICAL TRIALS -- DELIVERY,

IMMUNOGENICITY AND IMMUNE RESPONSE -- ADVERSE EFFECTS --
ADVANTAGES AND DISADVANTAGES -- ADVANTAGES AND
DISADVANTAGES OF DNA VACCINES -- ADVANTAGES OF RNA
VACCINES -- OPTIMIZATION -- DNA VACCINE OPTIMIZATION -- RNA
VACCINE OPTIMIZATION -- REFERENCES -- 11 - CANDIDATE CANCERS
FOR VACCINATION -- VACCINES FOR PROSTATE CANCER -- VACCINES
FOR MELANOMA -- VACCINES FOR LUNG CANCER -- VACCINES FOR
COLORECTAL CANCER -- VACCINES FOR BREAST CANCER --
REFERENCES -- 12 - OBSTACLES IN THE DEVELOPMENT OF
THERAPEUTIC CANCER VACCINES -- TUMOR ANTIGENS -- TUMOR
BURDEN -- CLINICAL RESPONSE VERSUS IMMUNE RESPONSE -- PRIOR
TREATMENTS -- DESIGNING CLINICAL TRIALS -- REFERENCES -- 13 -
COMBINATION THERAPY: CANCER VACCINES AND OTHER
THERAPEUTICS -- CHEMOTHERAPY COMBINED WITH VACCINES --
RADIATION COMBINED WITH VACCINES -- TARGETED THERAPIES
COMBINED WITH IMMUNOTHERAPY -- HORMONE THERAPY COMBINED
WITH VACCINE.
VACCINE COMBINED WITH OTHER IMMUNOTHERAPEUTIC MODALITIES
-- REFERENCES -- 14 - CONCLUDING REMARKS AND FUTURE
PERSPECTIVES ON THERAPEUTIC CANCER VACCINES -- CONCLUDING
REMARKS -- BASIC IMMUNOLOGY OF CANCER VACCINES -- APPROVED
VACCINES -- NEOANTIGEN VACCINES -- PREVENTIVE CANCER VACCINE
-- CONSIDERATIONS TO FULFILL AMBITIONS -- REFERENCES -- Index
-- Back Cover.
